Solstice Oncology logo
Solstice Oncology logo

Solstice Oncology

solsticeoncology.com
solsticeoncology.com • HQ: Boston, United States • Venture - Series Unknown 2026 • 51-200 employees • Founded 2026 • Startup
HQ: Boston, United States • Venture - Series Unknown 2026 • 51-200 employees • Founded 2026 • Startup
Actively hiring
Health Care
Oncology Therapeutics
Cell & Gene Therapy
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$121.3M
1 round on record
Latest round
$121.3M
Venture round · Feb 2026 · 7 mo ago
Team
51-200
employees, estimated range
Backers
1
RA Capital Management
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 20 Raised a round Venture round $121.3M · SEC Form D 2026 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Feb 2026 $121.3M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Solstice Oncology, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
David FeltquateExecutive OfficerSEC Form D
Maiken Keson-BrookesExecutive OfficerSEC Form D
Caroline LoewExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management fund
Investors in similar startupsfunds that back the companies most like this one
Foresite Capital
backs Lyell
Great Oaks Venture Capital
backs Lynx BiosciencesHealthfalse
Oxford Technology
backs Bioarchitech
Illumina Ventures
backs Actym Therapeutics
Longitude Capital
backs cAMPfield Therapeutics
Italian Angels for Growth
backs Lever Bio
Similar startupsby what they do, their industry and backers
T-knife TherapeuticsFounded 2018 • 51-200 employees
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer.
Lyell51-200 employees • 5 roles
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
BioarchitechVenture round · 10 mo ago • 11-50 employees
Bioarchitech develops multifunctional immunotherapies targeting cancer and virus-related diseases, including innovative viral and RNA-based…
Lynx BiosciencesHealthfalse
LynxBio is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated…
Lever BioSeed · 9 mo ago
Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
OncosenxVenture round $650k · 5 yr ago • Founded 2017 • 11-50 employees
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…

Overview

Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment, before surgery, to drive deep pathological response and return patients to lasting health. Our lead program is targeting colon cancer.

People

David Feltquate
Executive Officer
SEC Form D
Maiken Keson-Brookes
Executive Officer
SEC Form D
Caroline Loew
Executive Officer, Director
SEC Form D
Andrew Levin
Director
SEC Form D
Julie Grant
Director
SEC Form D
Emily Minkow
Director
SEC Form D
Morgan Haller
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston United States
HQ
50-200 est. staff

Financials

Total raised
$121.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 $121.3M Details